Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Telix Pharmaceuticals (TLX.AX)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (A$)	Price Target (A$)	Rating
2022-04-14	4.67	-	No Rating
2023-05-22	11.48	14.00	Buy
2024-01-23	11.15	13.00	Buy
2024-02-24	10.52	18.50	Buy
2024-04-17	12.54	19.30	Buy
2024-05-21	15.39	26.00	Buy
2024-07-24	18.85	28.00	Buy
2024-08-18	19.19	29.00	Buy
2024-09-27	20.44	31.00	Buy
2024-11-06	22.86	32.00	Buy
2025-01-27	27.53	35.00	Buy
2025-02-22	30.12	36.00	Buy

Disclosures

UBS Securities LLC makes a market in the securities and/or ADRs of this company.
UBS holds a long or short position of 0.5% or more of the listed shares of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.